Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
TRAXthis companyFirst Tracks Biotherapeutics Inc	$49.18	-3.98×	2.3×	0×	-2.47×	-85.9%	0.0%	0.0%	0.0%	-57.8%	-59.4%	-21.7%	0.05×	1.27×	0×	10.2×	0.0%	—	—	2	C
ACRSAclaris Therapeutics, Inc.	$4.22	-5.68×	3.58×	47.18×	-5.45×	-122.2%	73.3%	-975.9%	-829.6%	-63.0%	-57.7%	-12.8%	0.02×	0.28×	0×	5.28×	0.0%	2	-2.65	1	D+
ANABAnaptysBio, Inc.	$47.82	-70.26×	24.14×	3.83×	9.73×	-639.3%	99.0%	20.4%	-5.6%	-35.6%	14.6%	2.2%	0.38×	-3.24×	0.6×	9.07×	0.0%	5	2.21	3	B
ATATTOAttovia Therapeutics, Inc.	$16.29	-15.42×	6.25×	698.03×	-13.67×	-93.5%	40.4%	-4974.7%	-4490.9%	-40.2%	-42.8%	-6.5%	0.03×	0.53×	0×	14.2×	0.0%	—	—	2	C
CLYMClimb Bio, Inc.	$11.22	-4.55×	1.69×	0×	-3.95×	-95.0%	0.0%	0.0%	0.0%	-37.3%	-42.2%	-20.1%	0×	0.59×	0×	15.16×	0.0%	2	48.03	2	C
ELDNEledon Pharmaceuticals, Inc.	$2.77	-2.7×	1.52×	0×	-2.24×	-91.0%	0.0%	0.0%	0.0%	-56.3%	-55.1%	-50.4%	0.01×	0.49×	0×	7.4×	0.0%	1	-4.22	2	C
Peer median	—	-5.68×	3.58×	3.83×	-3.95×	-95.0%	40.4%	0.0%	-5.6%	-40.2%	-42.8%	-12.8%	0.02×	0.49×	0×	9.07×	0.0%	2	-0.22	2	—